Get started
Author

Prerak Shah

Observed names: P Shah, P. Shah
OpenAlex ID: A5000835489
Current trends in large cell lymphoma
2003 · R I Fisher, P Shah · Leukemia · 50
The Antitumor Activity of IMGN529, a CD37-Targeting Antibody-Drug Conjugate, Is Potentiated by Rituximab in Non-Hodgkin Lymphoma Models
2017 · Stuart W. Hicks, Katharine C. Lai, et al. · Neoplasia · 34
PDF
Evaluation of Targets for Maytansinoid ADC Therapy Using a Novel Radiochemical Assay
2015 · Katharine C. Lai, Jutta Deckert, et al. · Pharmaceutical Research · 11
Abstract 2900: Evaluation of endoglin/CD105 as a tumor vasculature target with antibody drug conjugates
2018 · Rui Wu, Cristina Gavrilescu, et al. · Cancer Research · 2
Abstract 4504: Plasma pharmacokinetics and tumor accumulation in mice of IMGN779, an antibody-drug conjugate for acute myeloid leukemia
2015 · Katharine C. Lai, Prerak Shah, et al. · Cancer Research · 1
Abstract 1073: Increased internalization and processing of the CD37-targeting antibody-drug conjugate, naratuximab emtansine (IMGN529), in the presence of rituximab leads to enhanced potency in diffuse large B-cell lymphoma models
2017 · Stuart W. Hicks, Katharine C. Lai, et al. · Cancer Research
642 Use of high dose fractionated cyclophosphamide and coordinated high dose methotrexate and cytarabine in childhood B cell Non Hodgkin's Lymphoma
2003 · S. Sandip, N. Shah, et al. · European Journal of Cancer Supplements
Works count: 7
Citation count: 98
H-index: 3
I10-index: 3
Year
Topic
Type